Key points from article :
Celularity Inc, a regenerative medicine company working at the intersection of biotechnology and aging science, has raised up to $12 million in new financing as it seeks to stabilise its business and sharpen its long-term strategy. The funding arrives during a difficult period for the company, whose share price and market value have fallen sharply over the past year. Backed by Philip A. Barach, co-founder of DoubleLine Capital, the deal is framed not as a quick fix but as patient, near-term support to give the company breathing room.
Rather than expanding into multiple areas, Celularity says it will use the capital to focus on its core technology: therapeutic products derived from the human placenta. These postpartum placental cells can be collected ethically after birth and are thought to have potential roles in tissue repair, immune modulation and processes linked to aging. CEO Robert J. Hariri said the financing will provide flexibility to refine priorities and concentrate resources on the most promising programmes.
One of Celularity’s most advanced candidates, PDA-002, is being developed to treat diabetic foot ulcers, a severe complication of diabetes that is especially common in older adults. In a Phase 2 clinical trial involving 159 patients across 35 US sites, the lowest dose of PDA-002 led to complete wound closure in 38.5% of patients, compared with 22.6% in the placebo group. While not a classic “longevity drug”, such treatments align with the broader goal of extending healthspan by preserving mobility and preventing chronic, disabling conditions.
Overall, the funding highlights a common challenge in longevity and regenerative medicine: strong scientific ideas often collide with financial pressure. Celularity’s new capital does not remove its risks, but it does give the company time to regroup, streamline its pipeline and clarify how its placental-derived technologies might fit into the evolving longevity landscape.
